Journal: iScience

Article Title: Rapid determination of sphingosine 1-phosphate association with carrier molecules by flow-induced dispersion analysis to predict sepsis outcome

doi: 10.1016/j.isci.2024.111168

Figure Lengend Snippet:

Article Snippet: C17-S1P , Avanti Polar Lipids , 860461P.

Techniques: Recombinant, Software, Mass Spectrometry

Journal: Journal of Neurology, Neurosurgery, and Psychiatry

Article Title: CSF sphingolipids are correlated with neuroinflammatory cytokines and differentiate neuromyelitis optica spectrum disorder from multiple sclerosis

doi: 10.1136/jnnp-2024-333774

Figure Lengend Snippet: Internal standards for lipidomics

Article Snippet: LacCer(d18:1/12:0) , Avanti Polar Lipids , 860545P , 0.5 , 806.6(M+H) + , 264.3 , 10.6.

Techniques: Biomarker Discovery

Journal: bioRxiv

Article Title: Automated and parallelized microfluidic generation of large and precisely-defined lipid nanoparticle libraries

doi: 10.1101/2025.05.26.656157

Figure Lengend Snippet: Physicochemical characterization of the LNP libraries generated by the LIBRIS chip. (A) Schematic of the potential design space assayed in this library. Across each lipid set, IL and cholesterol mole percent ratios vary directly proportionally with one another, which vary inversely with the phospholipid and PEG lipid ratios. A decrease in LNP size is shown with increased PEG concentration, schematized in the top right of the subpanel. (B) DLS measurements of the size of each formulation. (B, insets) Size decays exponentially with the molar percentage of PEG (MC3: P < 0.0001, SM-102: P < 0.0001, C12-200: P < 0.0001). (C, D) 95 / 96 particles and 93 / 96 particles fall within physicochemical benchmarks of encapsulation efficiency (EE%) and polydispersity index (PDI).

Article Snippet: The C12-200 library comprised the lipids C12-200 (Cayman Chemical), 1,2-dioleoyl-sn-glycero-3-phosphoethanolamine (DOPE, Avanti Polar Lipids), cholesterol, and 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-[amino(polyethylene glycol)-2000] (DSPE-PEG 2000, Avanti Polar Lipids) at concentrations of 2.22mg/mL, 0.66mg/mL, 1.00mg/mL, 0.38 mg/mL respectively.

Techniques: Generated, Concentration Assay, Formulation, Encapsulation

Journal: bioRxiv

Article Title: Automated and parallelized microfluidic generation of large and precisely-defined lipid nanoparticle libraries

doi: 10.1101/2025.05.26.656157

Figure Lengend Snippet: In vitro and in vivo validation of differences between LNPs in libraries shown by physicochemical characterization. (A) Heat map of the % of mCherry + HepG2 cells across all 96 LNPs screened. The lowest and highest transfecting C12-200 LNP moved forward from the in vitro screen into in vivo testing. (B) Representative IVIS images of the major organs extracted from one member of each cohort 6hr after LNP administration showing luciferase expression in the liver (H, heart; Lu, lungs; Li, liver; Sp, spleen; Ki, kidneys). (C) Quantification and analysis of hepatic luciferase expression between each treatment group. Normality of each sample distribution was validated by a Shapiro-Wilk test (PBS: P = 0.5881, F 4: P = 0.5913, F 24: P = 0.3048, BF: P = 0.6586). One-way ANOVA followed by Tukey’s HSD test was used to compare total luminescence between all groups (* P < 0.05, ** P < 0.01). n = 4 mice in PBS group. n = 6 in treatment groups.

Article Snippet: The C12-200 library comprised the lipids C12-200 (Cayman Chemical), 1,2-dioleoyl-sn-glycero-3-phosphoethanolamine (DOPE, Avanti Polar Lipids), cholesterol, and 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-[amino(polyethylene glycol)-2000] (DSPE-PEG 2000, Avanti Polar Lipids) at concentrations of 2.22mg/mL, 0.66mg/mL, 1.00mg/mL, 0.38 mg/mL respectively.

Techniques: In Vitro, In Vivo, Biomarker Discovery, Luciferase, Expressing

Journal: The FASEB Journal

Article Title: ORMDL Proteins Turnover via Proteasome and Autophagy Is Cell‐Type Dependent and Tied to Ceramide Homeostasis

doi: 10.1096/fj.202502924RR

Figure Lengend Snippet: Regulation of ORMDLs stability in human RPE‐1 cells and mouse BMMCs. (A) Levels of ORMDLs, SPTLC1, SPTLC2, and total d18:1 ceramides (measured by LC‐ESI‐MS/MS) were assessed in human RPE‐1 cells and mouse BMMCs after 24‐h treatment with 10 μM myriocin or 10 μM FB 1 , and compared with untreated controls. (B) Quantification of ORMDLs, SPTLC1, SPTLC2, and the LC3‐II/LC3‐I ratio was performed in untreated RPE‐1 cells and BMMCs, and compared with cells treated for 24 h with 50 μM CQ or 10 μM MG132, as determined by immunoblotting. (C) Effects of p97/VCP inhibition by CB‐5083 on ORMDLs, SPTLC1, SPTLC2, the LC3‐II/LC3‐I ratio, ATF4, and p62 levels were assessed in RPE‐1 cells and BMMCs. Protein levels in (A‐C) were normalized to total protein loading using Ponceau S staining. Data are presented as geometric mean ± GSEM ( N = 4). Statistical analysis was performed using one‐way ANOVA with Tukey's post hoc test. Significance levels: p < 0.05 (*), p < 0.01 (**), p < 0.001 (***), p < 0.0001 (****); n.s., not significant.

Article Snippet: Briefly, 50 μL of homogenate was transferred to a 1.5 mL microcentrifuge tube (Cat# 780420, Brand GmbH, Wertheim, Germany), mixed with 25 μL of MilliQ water, and loaded with internal standards: 50 ng dhS1P d17:0 (Cat# 860655), 50 ng S1P d17:1 (Cat# 860641), and 25 ng C1P d18:1/C12:0 (Cat# 860531), each from Avanti Polar Lipids, dissolved in 5 μL of chloroform/methanol solution (2:1, v/v).

Techniques: Tandem Mass Spectroscopy, Western Blot, Inhibition, Staining